Roche has suffered a major setback in its goal to lead in a new class of cancer immunotherapies, with the surprise failure of its anti-TIGIT tiragolumab in non-small cell lung cancer.
Blow To Roche Growth Prospects As TIGIT Lung Cancer Trial Fails
Cancer Combination Fails In Phase III
Failure of the tiragolumab plus Tecentriq combination in first line NSCLC patients is a blow to Roche’s immunotherapy aspirations, and its long-term growth strategy.
More from Anticancer
More from Therapy Areas
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.